CA9 and lung carcinoma: CAIX was found to provide resistance to ferroptosis-inducing drugs such as erastin through inhibition of transferrin endocytosis and stabilization of ferritin, while treatment of gefitinib-resistant lung cancer cells with CAIX inhibitor SLC-0111 (U-104) in combination with cisplatin enhanced ferroptosis in vivo (Zhang et al., 2023).